News feeds from around the industry (Updated Hourly) - Updated on February 27, 2017 Bookmark and Share

Biotech News - Business Wire

>TheraVida Announces Publication of Phase 2 Results for THVD-102 in HyperhidrosisSAN MATEO, Calif.--(BUSINESS WIRE)--TheraVida releases Phase 2 data for THVD-102 in hyperhidrosis

>Arrakis Therapeutics Announces $38 Million Series A Financing to Target RNA with Small-Molecule Medicines and Names Michael Gilman Chairman and CEOWALTHAM, Mass.--(BUSINESS WIRE)--Arrakis Therapeutics announces $38 Million series A financing to target RNA with small-molecule medicines and names Michael Gilman, PhD as Chairman and CEO.

>Glaukos Announces Participation in 29th Annual ROTH ConferenceSAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the 29th Annual ROTH Conference on Monday, March 13, 2017, at 9:30 a.m. PDT in Laguna Niguel, California. A live audio webcast for this event will be available in the Investors sec

>Exelixis Announces Clinical Trial Collaboration with Roche to Evaluate Cabozantinib and Atezolizumab in Locally Advanced or Metastatic Solid TumorsSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced a new collaboration with Roche on a phase 1b dose escalation study that will evaluate the safety and tolerability of cabozantinib, Exelixis? tyrosine kinase inhibitor (TKI), in combination with atezolizumab, Roche?s anti-PD-L1 immunotherapy, in patients with locally advanced or metastatic solid tumors. Enrollment is scheduled to begin mid-year 2017; Exelixis will be the sponsor of the trial, and Roche wil

>Inotek Pharmaceuticals Announces Participation at Upcoming Investor ConferencesLEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals announces participation at upcoming investor conferences in March.

Biotech News - PR Newswire

>China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2017- 3Q17 Added 19,712 New Subscribers - 3Q17 Revenue Up 18.6% YOY to RMB200.9 Million ($28.9 Million) - 3Q17 Operating Income Reached RMB101.7 Million ($14.6 Million) - Conference Call to be Held on February 27, 2017 at 8:00 a.m. ET HONG KONG, Feb. 24, 2017 /PRNewswire/ -- Ch...

>Natural Trends, Anti-pollution Protection Claims, and New Technologies are the Cornerstones of the Specialty Actives Market's Strong Growth, Finds KlinePARSIPPANY, N.J., Feb. 24, 2017 /PRNewswire/ -- Driven by consumers' preference towards more natural products, botanicals and biotechnology are now the fastest growing categories, finds the recently published U.S. volume from the Specialty Actives in Personal Care: Multi-regional Market...

>DURECT Corporation Invites You to Join its Fourth Quarter 2016 Earnings Conference CallCUPERTINO, Calif., Feb. 24, 2017 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2016 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Tuesday, March 14, 2017 at 4:30 pm...

>Zimmer Biomet Holdings to Present at the Cowen and Company 37th Annual Health Care ConferenceWARSAW, Ind., Feb. 24, 2017 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, will present at the Cowen and Company 37th Annual Health Care Conference at the Boston Marriott Copley Place on Tuesday, March 7, 2017 at 11:20 a.m....

>BrainStorm Names Dr. June S. Almenoff and Arturo O. Araya to its Board of Directors as Company Prepares for Clinical and Commercial SuccessHACKENSACK, N.J. and PETACH TIKVAH, Israel, Feb. 27, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today the appointments of June S. Almenoff, M.D., Ph.D., FACP, and...

FDA News - Business Wire

>Acorda to Present at the Cowen and Company 37th Annual Healthcare ConferenceARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) will present at the Cowen and Company 37th Annual Health Care Conference in Boston on Monday, March 6, 2017 at 1:20 p.m. EST. A live audio webcast of the presentation can be accessed under ?Investor Events? in the Investor section of the Acorda website at, or you may use the link: An archived version of this webcast will be available until April 6, 2017 on the Investors sec

>BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0LONDON--(BUSINESS WIRE)--BTG plc (LSE: BTG), the global specialist healthcare company, today announced U.S. Food and Drug Administration 510(k) clearance has been granted to the EKOS® Control Unit 4.0. The EKOS® system includes an ultrasonic device that uses acoustic pulses, powered by the new Control Unit 4.0, to quickly and safely dissolve blood clots and restore blood flow in patients with pulmonary embolism (PE), deep vein thrombosis (DVT), and peripheral arterial occlusions (PAO). The EKOS

>CureDuchenne Ventures Invests in New Gene Editing Company Exonics Therapeutics to Advance CRISPR/Cas9 Therapy for Duchenne Muscular DystrophyNEWPORT BEACH, Calif.--(BUSINESS WIRE)--#CRISPR--CureDuchenne Ventures, a subsidiary of the nonprofit CureDuchenne that funds research to find a cure for Duchenne muscular dystrophy, announced today that they have committed $5 million in seed financing in Exonics Therapeutics, a new biotechnology company focused on utilizing gene editing technologies like CRISPR/Cas9 to advance the development of a treatment for Duchenne muscular dystrophy. Exonics? CRISPR/Cas9 technology is a potential one-t...

>Bristol-Myers Squibb to Take Part in Cowen and Company 37th Annual Global Health Care ConferenceNEW YORK--(BUSINESS WIRE)--$BMY--Bristol-Myers Squibb to Take Part in Cowen and Company 37th Annual Global Health Care Conference

>AV Medical's Chameleon? Receives Expanded Indication to Include Infusion of Diagnostic or Therapeutic FluidsTEL AVIV, Israel--(BUSINESS WIRE)--AV Medical Technologies, Ltd. announced today that its Chameleon? PTA balloon catheter has received FDA clearance for an expanded indication to include infusion of diagnostic or therapeutic fluids. ?The Chameleon? balloon offers advantages for experienced operators as well as those training in dialysis access procedures,? commented Dr. John Ross of the Dialysis Access Institute in Orangeburg, SC. ?We appreciate the efficiency that it provides to these cases as


>FierceBiotech Radio on pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilarsFiercePharma's Eric Palmer and FierceBiotech's Damian Garde discuss a bizarre congressional hearing, how biotech's slump affects the buyout climate, and a major development in the world of biosimilars.

>Pursuing new deals to grow the pipeline, Szela axes staffers in Aegerion reorgMary Szela, the new CEO at Cambridge, MA-based Aegerion, has reached for the budget ax to help compensate for the rising tide of competition that has challenged its cholesterol drug Juxtapid. The company announced today that it is chopping about 25% of its staff--roughly 80 workers--as it whittles its roster of employees down to 230.

>4D pharma buys Tucana to add diagnostic capabilities to microbiome R&D toolkit4D pharma has struck a deal to buy Tucana Health. The takeover, which is costing £3.1 million ($4.5 million) upfront with more tied to milestones, is intended to boost 4D pharma's ability to identify patients who may benefit from live biotherapeutics, starting with a treatment for irritable bowel syndrome.

>AveXis and Proteostasis survive the market storm, IPOs raise $145M for R&DThese days there are two kinds of biotech IPOs that make it to the market: The select few solid successes in line with the range and some bargain selections that provide a haircut on the price, where the company ups the number of shares but sells at a significant discount to the range. Another group are just quietly leaving their IPOs on the shelves or pulling out altogether to wait out the storm.

>Intercept books a date with the FDA as buyout rumors simmerAfter an FDA-mandated three-month delay, Intercept Pharmaceuticals is set for a meeting with agency advisers to discuss obeticholic acid, an in-development liver drug tabbed by analysts as a potential blockbuster.

FierceBiotech IT

>DNAnexus connects genomics platform to Sapio Sciences' LIMSDNAnexus has connected its genomics platform to Sapio Sciences' Exemplar laboratory information management system (LIMS). The integration is expected to provide clients with a sample-to-answer tracking system, a resource the collaborators see cutting costs while improving quality control.

>BioClinica rolls out tech-enabled postapproval research serviceThe division, which the company has set up to meet rising demand for postapproval research, will make use of BioClinica's technology capabilities.

>CosmosID raises $6M to advance microbiome bioinformatics offeringCosmosID has raised $6 million to advance its microbiome software business. The Series B round is intended to enable CosmosID to build out and enhance multiple aspects of its operation, with the expansion of engineering capabilities and improvement of genotype-phenotype linkage abilities high on its agenda.

>Illumina signs biobank deals to fuse genome data, EMRsIllumina has signed deals to genotype the sample collections at four biobanks. Each of the projects is aiming to build a repository of linked genotypic and phenotypic data, with the sequencing results generated by Illumina being paired to electronic medical records (EMRs) possessed by the owners of the biobanks.

>Stallergenes resumes work after IT-related shutdown, hires head of tech opsStallergenes Greer has resumed production at its plant that was blighted by IT problems. The restart of manufacturing comes nearly two months after regulators found the IT system introduced at the site in August was causing operational disruptions and erroneous product deliveries.

FierceBiotech Research

>Investigators at The Hutch draw up a new battle plan for metastasisResearch coming from the Fred Hutchinson Cancer Research Center and Johns Hopkins Medical Institute concludes that the deadly spreading of cancer occurs in clusters rather than single cancer cells.

>U.K. scientists get a green light to modify human embryosFertilization experts in the U.K. have been given a green light to start modifying human embryos, an experiment which they expect will give them unique insights into the way in which an embryo transforms into a healthy baby.

>Gene therapy pioneer James Wilson uses CRISPR/Cas9 to target liver disease One of the pioneers in the whole gene therapy movement of the past 35 years has combined his knowledge of viral vectors with the hot new CRISPR/Cas9 tech to tackle a rare genetic liver disease. And his work with rodents highlighted both the promise of this new technology as well as an unexpected hurdle.

>Researchers discover fusion protein that promotes cancer via three distinct ways in pediatric brain tumorsScientists at The Children's Hospital of Philadelphia (CHOP) and the Dana Farber Cancer Institute have uncovered an important cancer-driving fusion protein that promotes a pediatric brain tumor via three distinct mechanisms.

>Oxford team fingers an inflammatory protein as a trigger for cancerResearchers from Oxford University working on a protein named PAD4 have made new tracks in identifying its role in cancer, spotlighting a new therapeutic strategy for cancer drug hunters.


>Pfizer builds on early Ibrance lead as Novartis, Lilly rivals inch closerPfizer's Ibrance has already been prescribed to more than 20,000 patients, and the company says it has a "very heavy" clinical trial program testing it in multiple types of breast cancer and beyond.

>Some top GSK investors aren't sold on a breakup--and they're backing CEO Witty, tooSome of GlaxoSmithKline's prominent investors may be pushing for a four-way breakup of the company. But others are just fine preserving the status quo--and keeping CEO Andrew Witty at the helm to do it.

>After a big 2015, Regeneron predicts slowing 2016 sales for launch superstar EyleaLast month, Regeneron announced 2015 Eylea sales that had investors excited. But that didn't soften the blow on Tuesday, when it warned that the med's growth in the U.S. would slow down.

>Top Senate Democrat grills HHS about opioid panel's alleged ties to industryAbout a third of panelists at a Department of Health and Human Services (HHS) meeting on painkiller prescribing had financial ties to companies that make the drugs, a recent report showed. A top Senate Democrat is not pleased with those findings, and he's grilling the HHS about the members' relationships with the industry.

>Sanofi's outlook less than sunny as key diabetes franchise continues to sagSanofi delivered a good-news, bad-news set of fourth-quarter results: Earnings better than expected and solid growth in emerging markets, but shortfalls in overall revenue and operating profits. Its follow-up to big-selling Lantus, Toujeo, beat projections, but its long-anticipated cholesterol fighter, Praluent, brought in just a few million euros.

FiercePharma Manufacturing

>FDA quality focus will definitely mean winners and losers, report saysThe FDA intends to change the way it handles plant inspections, using metrics to suggest which plants may be having issues and making more frequent trips to those that appear at risk. While those companies committed to quality may be rewarded for their efforts, a new report warns that those that are already struggling with quality can expect to be more under the thumb of regulators.

>FDA warning to Ipca Labs shines light on rampant data falsificationFDA inspectors have cited data manipulation and falsification at any number of manufacturing facilities in India, but a new warning letter for three Ipca Laboratories plants shows that it was rampant at that company, enforced by senior managers in the quality-control unit to keep product supply flowing.

>Report says CMOs without U.S. facilities risk being left out of 'hot' market A new report from CPhI of the U.S. market says that international API and drug manufacturers need to consider investing in U.S. manufacturing sites as drugmakers look to source products in the U.S. because of concerns over quality in some other countries.

>Dr. Reddy's grows U.S. sales even in face of FDA actionThree of Dr. Reddy's Laboratories' key plants were singled out in a warning letter after FDA inspectors tallied up a host of data manipulation and contamination violations. But India's third-largest drugmaker was still able to grow sales in the U.S. last quarter even with production at the three facilities interrupted by remediation efforts.

>Regulator suspends Spanish drugmaker over 'critical quality defects' Regulators in Spain are punishing a Barcelona-based drugmaker for a series of manufacturing shortfalls, recalling all batches produced by the company, Farma Mediterrania, from 2014 to present. The crackdown is the second in as many months by Spanish authorities on local producers.


>Merck, J&J, Pfizer consider joining Zika vaccine raceWhile the early entrants to the race for a Zika vaccine have been on the smaller side--think Hawaii Biotech, NewLink Genetics and Inovio Pharmaceuticals--the big guns are now joining in. Just one day after Sanofi announced a firm plan to develop a vaccine for the mosquito-borne disease, a parade of Big Pharmas has joined GlaxoSmithKline in "evaluating their technologies" for the potential of developing a Zika vaccine.

>Pfizer's vaccine sales leap in 2015 thanks to Prevnar 13Riding Prevnar 13 uptake, Pfizer's vaccines unit capped off a big growth year on Tuesday, reporting Q4 sales increases of 45% and full-year 2015 growth of 44%.

>Affinivax nets another $2.5M from Gates Foundation to advance Prevnar competitorCambridge, MA-based Affinivax launched in November 2014 with a $4 million Gates Foundation investment and plans to develop a pneumococcal vaccine that it believes could go beyond Prevnar, the best-selling vaccine in the world. Now, the biotech is announcing $2.5 million in follow-on funding from the Gates Foundation, which it will use to advance its lead candidate, CEO Steve Brugger told FierceVaccines.

>UT Southwestern team creates new drug that could aid in vaccine developmentResearchers at UT Southwestern Medical Center have discovered a new drug that could help in vaccine development. It activates the innate immune system in a novel way.

>NCI's Cancer Centers join in HPV vaccination pushAll 69 of the United States' National Cancer Institute-designated centers have joined together to issue a statement urging an increase in HPV vaccinations, declaring the vaccines "tragically underused" and calling low uptake a "public health threat."

Health News -

>Humana CEO Broussard, other industry execs to meet with Trump todayHumana Inc. president and CEO Bruce Broussard and other health insurance industry executives will meet with President Donald Trump today. Reuters reports that other companies sending their leaders to the meeting include Cigna Corp. and the Blue Cross Blue Shield Association. Bloomberg also reported about the meeting, which had not been confirmed by the White House as of Friday afternoon. Trump has pledged to repeal and replace the Affordable Care Act. As Reuters reports, it is not cl...

>How the state's newest Duchenne biotechs are getting a boost from patient groupsPatient advocacy groups appeared to play an important role in helping Cambridge-based Sarepta Therapeutics secure FDA approval last year for the first-ever Duchenne muscular dystrophy drug ? and the latest local entrants to the field have taken notice. On Friday, Swiss drugmaker Santhera Pharmaceuticals held a grand opening ceremony for a new office in Burlington, Mass., the company?s first in the U.S. Top executives at Santhera, which has a DMD treatment in a Phase 3 trial, said in interv...

>Biogen alums team up to launch Waltham biotech, with backing from Henri TermeerA new biotech has launched in Waltham with a management team made up of former Biogen executives and $38 million in financing from Pfizer, former Genzyme CEO Henri Termeer and other prominent investors. Arrakis Therapeutics said it will focus on developing potential treatments for neurology, cancer and rare genetic disorders that target RNA, the all-important molecules that translate the instructions in DNA into proteins in the body. The $38 million Series A financing was led by Califor...

>Delaware biopharm company moves to S&P 500, inks alliance with PennA Delaware-based biopharmaceutical company is headed to the S&P 500, a change that will become effective at the start of trading on Tuesday. Incyte (NASD:INCY) will replace Spectra Energy Corp. (NYSE:SE) on the biotechnology sub-industry index. The announced shift came a day after the Wilmington biopharma firm and University of Pennsylvania announced a new research alliance that will focus on assessing new cancer treatments under development and advancing immunotherapy to fight cancer. ...

>'Growth mode' sandbags Mayo Clinic profitsMayo Clinic's income fell to nearly five-year lows in 2016 as the health system boosted investments in facilities and technology. The Post-Bulletin reports on the annual financial report from Rochester, Minnesota-based Mayo, which posted operating income of $475 million last year, the lowest figure since 2012 and down from $526.4 million in 2015. Operating margin was down sharply, too, from 5.1 to 4.3 percent. Revenue, however, climbed to nearly $11 billion, from $10.3 billion in 2015. ...

Marketwire - Pharma and Biotech

>ORYZON Reports Financial Results and Corporate Update for the Fourth Quarter and Year Ended December 31, 2016 BARCELONA, SPAIN and CAMBRIDGE, MA--(Marketwired - February 24, 2017) - Oryzon Genomics (MAD: ORY) (ISIN Code: ES0167733015), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the fourth quarter of 2016 and provided an update on the Company's recent developments.

>Dr. Timothy Greco Now Offers Volbella(R) in PhiladelphiaBy adding Juvederm Volbella(R) to his Philadelphia-area practice, Dr. Timothy Greco kicked off 2017 with more options than ever for patients looking for nonsurgical cosmetic options for the face

>RepliCel Life Sciences Announces Closing of Brokered and Non-brokered Private Placement VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 24, 2017) -

>Elsevier Updates Infectious Diseases Reference Aimed at Controlling and Preventing Neglected and Emerging Worldwide DiseasesAlso publishes five additional immunology, virology and microbiology books

>Diet Doc Offers Weight Loss And Weight Maintenance Alternatives To The Dangerous Original hCG DietPHOENIX, AZ--(Marketwired - February 27, 2017) - Even after following a consistent weight loss process and achieving positive results, many obese and overweight individuals experience weight regain. Weight maintenance depends on a variety of factors, including genetics, personal behavior, and the environment. Following a regular diet and reducing daily caloric intake also has a significant effect. Behavioral therapy may be provided to those continuously struggling with weight regain. The sta...

Medical Pharma - PR Newswire

>John Theurer Cancer Center's Dr. Andre Goy Co-Chairs 21st Annual International Congress on Hematologic MalignanciesHACKENSACK, N.J., Feb. 27, 2017 /PRNewswire/ -- Andre Goy, M.D., Chairman and Director, Lydia Pfund Chair for Lymphoma, John Theurer Cancer Center at Hackensack University Medical Center and Professor of Medicine at Georgetown University, co-chaired the 21st Annual International Congress...

>Flexpoint Ford Partners with SouthEast Eye Specialists and Center for Facial RejuvenationCHATTANOOGA, Tenn., Feb. 27, 2017 /PRNewswire/ -- Flexpoint Ford, LLC ("Flexpoint Ford"), a private equity firm focused on the healthcare and financial services sectors, announced today that it formed a partnership with SouthEast Eye Specialists and its affiliates ("SouthEast Eye...

>New Cancer Therapeutics Drive the Cancer Biological Therapy MarketNEW YORK, February 27, 2017 /PRNewswire/ -- Increased need for better cancer treatment continues to boost the global cancer biological therapy market. According to a report published by Global Market Insights, cancer biological therapy market size is expected to reach USD 100 billion...

>NoNO Inc Initiates Phase III Study of NA-1 for Acute Ischemic StrokeA Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects with Acute Ischemic Stroke Undergoing Endovascular Thrombectomy (ESCAPE-NA1 trial; NCT02930018) TORO...

>Medical Device Analytical Testing Outsourcing Market to Reach $8.3 Billion by 2025 - Outsourcing to Minimize Business Risks, Hasten Product Market Entry & Reduce Costs - Research and MarketsDUBLIN, Feb 27, 2017 /PRNewswire/ -- Research and Markets has announced the addition of the "Medical Device Analytical Testing Outsourcing Market (2014- 2025" report to their offering. The global medical device analytical testing outsourcing market is expected to reach USD 8.3...


>Help Wanted | Departmental EIR at a University Near You!Let?s face it, the Technology Transfer Office (TTO) has an exceedingly difficult and complex job to do. And if not executed to perfection, while faced with so many variables beyond control of the Office, heads may easily and frequently roll. How can we possibly improve TTO performance? And, why should we even care to? At […]

>License Agreement: Clovis Oncology $CLVS (Celgene, $CELG)May 2010, $CLVS entered into an exclusive worldwide license agreement with Avila Therapeutics, Inc. (now Celgene Avilomics Research Inc., part of Celgene Corporation $CELG) to discover, develop and commercialize a covalent inhibitor of mutant forms of the EGFR gene product. As a result of the collaboration contemplated by the agreement, rociletinib was identified as the […]

>License Agreement: Clovis Oncology $CLVS (Ethical Oncology Science, S.p.A, Servier, SA, and Advenchen Laboratories, LLC)November 2013, Clovis Oncology ($CLVS @ClovisOncology) acquired Ethical Oncology Science, S.p.A. (?EOS?) (known as Clovis Oncology Italy S.r.l., or ?COI?) through which the rights to lucitanib were obtained. 2008, EOS had in-licensed exclusive development and commercial rights to lucitanib on a global basis, excluding China, from Advenchen Laboratories. September 2012, EOS entered into a collaboration and license […]

>License Agreement: Clovis Onclology $CLVS (Pfizer, $PFE)June 2011, Clovis Oncology ($CLVS @ClovisOncology) entered into a license agreement with Pfizer ($PFE @Pfizer) to obtain exclusive global rights to develop and commercialize rucaparib. The rights are exclusive even as to Pfizer and include the right to grant sublicenses. Upfront Payment $7.0MM Milestone 1 $0.4MM, April 2014, for the initiation of ARIEL3 pivotal registration study Milestone 2.0 $88.5MM […]

>Summary: Array BioPharma $ARRYWe will spend the next few sessions illuminating Array Biopharma?s (ARRY) ($ARRY) robust pipeline of clinical and pre-clinical stage partnered assets and discovery programs. To include:  

Pharma News - Business Wire

>Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual MeetingBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune will present AR101 clinical data in peanut allergy at the 2017 AAAAI annual meeting on March 6 in Atlanta, Georgia.

>Digestive Enzyme Supplements Market to Reach $1.6 Billion by 2025 - Increasing Incidence of Gastrointestinal Tract Diseases - Research and MarketsDUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Digestive Enzyme Supplements Market Forecasts 2014-2025" report to their offering. The global digestive enzyme supplements market is expected to reach USD 1.6 billion by 2025. Growing consumer awareness regarding the severity of digestive disorders coupled with the need for good health is expected to stimulate industry growth over the forecast period. The increasing incidence of gastrointestinal tract diseases, suc

>Syros Reports Discovery of Novel Genomics Based Approach to Stratifying Patients with Acute Myeloid Leukemia at Cold Spring Harbor ConferenceCAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced the discovery of a novel genomics based approach to stratify acute myeloid leukemia (AML) patients based on super-enhancer profiles.1 In their research, Syros scientists demonstrated a strong association between distinct super-enhancer profiles of six AML patient clusters and

>Walgreens Boots Alliance Publishes Corporate Social Responsibility Report 2016DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. today released its annual Corporate Social Responsibility Report for fiscal 2016, highlighting the company?s ongoing CSR work.

>Global Viral Partnering 2010-2017: Deal Trends, Players and Financials - Research and MarketsDUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Viral Partnering 2010-2017: Deal trends, players and financials" report to their offering. Global Viral Partnering 2010 to 2017 provides the full collection of Viral disease deals signed between the world's pharmaceutical and biotechnology companies since 2010. The report takes readers through the comprehensive Viral disease deal trends, key players and top deal values allowing the understanding of how, why

Pharma News - PR Newswire

>$8.8 Billion Cardiac Resynchronization Therapy (CRT) Market - Analysis By Product (Cardiac Resynchronization Therapy Pacemakers [CRT-P], Cardiac Resynchronization Therapy Defibrillators [CRT-D]) - Research and MarketsDUBLIN, Feb 27, 2017 /PRNewswire/ -- Research and Markets has announced the addition of the "Cardiac Resynchronization Therapy (CRT) Market (2014-2025)" report to their offering. The global cardiac resynchronization therapy (CRT) market is expected to reach USD 8.8 billion by...

>Technical Reports on Generic Drugs Stocks -- Zoetis, Mallinckrodt, Akorn, and MYOS RENS TechnologyNEW YORK, February 27, 2017 /PRNewswire/ -- This morning's research directs the attention of to the following Generic Drugs stocks: Zoetis Inc. (NYSE: ZTS), Mallinckrodt PLC (NYSE: MNK), Akorn Inc. (NASDAQ: AKRX), and MYOS RENS Technology Inc. (NASDAQ: MYOS). These...

>Landmark Study: Meta-Analysis of 28 Studies Shows Stretta Therapy for GERD Consistently and Significantly Improves OutcomesNORWALK, Conn., Feb. 27, 2017 /PRNewswire/ -- Mederi Therapeutics today announced the publication of a meta-analysis of 28 studies, representing 2468 patients who received Stretta Therapy to treat gastroesophageal reflux disease (GERD). The study entitled, "Systematic Review and Meta-Analy...

>Bracco Diagnostics Inc. Receives U.S. FDA Approval for VARIBAR® PUDDING (barium sulfate) oral paste for FluoroscopyMONROE TOWNSHIP, N.J., Feb. 27, 2017 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, today announced the U.S. Food and Drug Administration (FDA) approved VARIBAR PUDDING for modified barium...

>Allergan's New Eyepowerment? Campaign Urges The Up To 33 Million Americans Suffering from Symptoms of Chronic Dry Eye to Take ActionDUBLIN, Feb. 27, 2017 /PRNewswire/ -- "Before we had our voice, we had our eyes," is the powerful opening message from Allergan's new campaign to raise awareness for Chronic Dry Eye. The campaign, titled "Eyepowerment," aims to empower individuals who may be struggling with symptoms of...

Xconomy Life Sciences

>After Navigating Ups and Downs, Cellectar CEO Caruso Looks to FutureCellectar Biosciences has seen ups and downs in the last 18 months, including several changes in its top ranks. Now, as the cancer drug developer prepares to take its lead drug candidate into mid-stage clinical trials, CEO Jim Caruso seems more interested in talking about his company?s future than its past. Madison, WI-based Cellectar (NASDAQ: […]

>Cashing in On Duchenne Approval, Sarepta Sells Voucher to Gilead For $125MSarepta Therapeutics didn?t just get its first drug to market when the FDA approved the Duchenne muscular dystrophy drug eteplirsen (Exondys 51) last year—it got a potentially lucrative voucher from the FDA too. Today the Cambridge, MA, company cashed that in. Sarepta (NASDAQ: SRPT) this morning sold what?s known as a priority review voucher to […]

>Argos Shares Crater on Futility Finding for Kidney Cancer TherapyAn Argos Therapeutics therapy that uses the immune system to fight kidney cancer has hit a wall after an analysis of the latest clinical trial data found that the experimental treatment was unlikely to work. Following the planned interim analysis of Argos?s (NASDAQ: ARGS) Phase 3 clinical trial, the independent data monitoring committee recommended stopping […]

>Genomenon's Software Seeks to Give Geneticists Faster InsightsGenomenon, a University of Michigan spinout developing analytics and data visualization software for the genomics industry, released its first product last week: software designed to simplify the process of interpreting gene variants. Called Mastermind, the software is a tool that automatically combs through millions of journal articles and medical publications; its goal is to drastically […]

>Cidara Antifungal Flunks in Phase 2 Clinical Trial, Sinking SharesCidara Therapeutics is halting work on an experimental topical antifungal drug designed to treat vaginal yeast infections after the compound wasn?t better than the current standard of care in a Phase 2 clinical trial. San Diego-based Cidara (NASDAQ: CDTX) said in a statement on Tuesday it will now shift its resources to other compounds in […]